Today announces that the consortium.

Related StoriesAnalyzing potential TB vaccineNew vaccine candidate shows great promise at fighting respiratory syncytial virusKey component of MRSA vaccine puzzle unearthed Apitope's antigen-particular disease modifying peptide therapy uses epitopes designed to shut down the abnormal immune responses to the causative agent in an extremely selective manner, re-instating the standard immune balance, avoiding global immune suppression thereby. As a result, the peptides taken into scientific evaluation by Apitope offer the potential to possess limited side effects and a good probability of efficacy. Dr. Keith Martin, CEO of Apitope mentioned: Graves' Disease can be an illness with serious implications especially for those with Graves' orbitopathy who are at risk of blindness.Patients who want corneal transplants are usually 50 and older. Relating to projections by the U.S. Census Bureau, that human population will grow from about 99 million in 2010 2010 to about 133 million by 2030 in this country. While the number of patients will grow the number of potential donors is certainly waning. All of these issues disqualify potential donors: meals contamination, such as for example mad cow disease and the latest listeria outbreak in cantaloupe; the growing amount and spread of infectious diseases such as HIV and West Nile virus and the tropical disease chikungunya, which have no remedy; high-risk behaviors such as methamphetamine use – which is at epidemic levels in a few parts of the country – IV drug use and imprisonment; the growing number of people identified as having Alzheimer’s or additional neurologic diseases of unknown origin; and the ageing human population itself, which is less suited to donate because corneas deteriorate and age; described Dr.